[Polyethylene glycol-adenosine deaminase: a new adenosine deaminase deficiency therapy. Value of deoxyadenosine triphosphate determination for therapeutic monitoring].

Published

Journal Article

The effect of polyethylene glycol-adenosine deaminase (PEG-ADA) therapy on biochemical, immunological and clinical abnormalities in an ADA-deficit child with severe combined immunodeficiency has been studied. Following PEG-ADA therapy, total lymphocytes, lymphocyte subsets (CD3, CD4 and CD8) and the response of lymphocytes to non specific mitogens increase significantly. The improvement of immunological functions is closely related to a decrease of erythrocyte deoxyadenosine triphosphate (dATP) concentrations. This study shows that PEG-ADA therapy is sufficiently effective to reduce and to maintain erythrocyte dATP levels at values compatible with normal immune functions. PEG-ADA represents an important progress for the treatment of ADA deficiency associated with severe combined immunodeficiency disease.

Full Text

Duke Authors

Cited Authors

  • Bory, C; Boulieu, R; Souillet, G; Hershfield, MS

Published Date

  • July 1991

Published In

Volume / Issue

  • 46 / 4

Start / End Page

  • 323 - 326

PubMed ID

  • 1948809

Pubmed Central ID

  • 1948809

International Standard Serial Number (ISSN)

  • 0040-5957

Language

  • fre

Conference Location

  • France